Form 4: Cyclo Therapeutics Director Receives Stock Grant in Lieu of Cash Compensation

William S. Shanahan, a director at Cyclo Therapeutics, Inc., acquired 7,937 shares of common stock on August 16, 2024, as compensation for the second quarter of 2024.

Summary

• On August 16, 2024, William S. Shanahan, a director of Cyclo Therapeutics, Inc. (CYTH), acquired 7,937 shares of common stock.
• The shares were received as a grant in lieu of cash compensation under the company's non-employee director compensation policy.
• The grant reflects director compensation for the second quarter of 2024.
• The number of shares was calculated based on a closing price of $1.26 per share on August 16, 2024.
• Following the transaction, Shanahan directly owns 133,681 shares of Cyclo Therapeutics.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The director accepting stock in lieu of cash suggests confidence in the company, but it's a routine transaction.

Positives

• The director's decision to take stock in lieu of cash demonstrates confidence in the company's future prospects.
• The grant aligns the director's interests with those of the shareholders.

Future Outlook

There is no future outlook provided in this document.

Industry Context

Director compensation in the form of stock grants is a common practice in publicly traded companies to align the interests of management with those of shareholders. This filing indicates standard compensation practices at Cyclo Therapeutics.

Comparison to Industry Standards

• Stock grants are a typical component of director compensation packages across various industries.
• The size of the grant is likely determined by factors such as company size, performance, and industry benchmarks for director compensation.
• Comparing Cyclo Therapeutics' director compensation practices with those of similar-sized biotech companies would provide further context.

Stakeholder Impact

• The stock grant to the director aligns their interests with shareholders, potentially leading to decisions that benefit the company's long-term value.
• The transaction has a minor dilutive effect on existing shareholders.

Key Dates